Hygeia Healthcare (Hygeia) released its voluntary 2026 interim results, ahead of a conference call scheduled for 28 August 2026. The oncology-focused hospital group reported resilient profitability, tighter working-capital management and a reinforced shareholder-return framework.
Financial performance • Revenue slipped 1.4% year on year to RMB1.96 billion for the six months ended 30 June 2026. • Net profit climbed 4.7% to RMB260 million, lifting net margin by 0.7 percentage point to 13.1%. • Gross profit margin improved 0.8 percentage point to 27.4%. • EBITDA was broadly stable at RMB460 million (+0.1% YoY) and free cash flow matched this level. • Operating cash flow rose 38.5% to RMB300 million, taking operating cash flow/net profit coverage to 178.2%.
Balance-sheet and cash discipline • Trade receivables contracted to RMB548.70 million at 30 June 2026, down 33.3% from end-2024 and 20.1% from end-2025. • Interest-bearing debt-to-asset ratio moderated to 21.3%, versus 22.8% at end-2025 and 25.4% at end-2024. • Capital expenditure fell to RMB162.40 million in 1H26, 52.0% lower than the prior-year period, underscoring a more selective investment approach.
Operational trends • Total patient visits reached 2.30 million (+4.1% YoY); outpatient volume rose 4.5% to 1.80 million. • Surgeries increased 8.2% to 46,000, with higher-complexity (Level 3/4) procedures up 17.8% to 21,000. • The group counts 929 full-time senior medical professionals, 22 more than at end-2025, and now operates 38 clinical key specialties, four more than at year-end.
Strategic initiatives • Critical-care capacity advanced: Suzhou Yongding Hospital secured national chest-pain-centre certification, while Chang’an and Hezhou Guangji Hospitals achieved top provincial DRG rankings. • International medical services expanded, with Chongqing Hygeia Hospital adding three floors of international wards and attracting patients from Southeast Asia, Central Asia, Europe and the US. • Self-pay offerings—ranging from oncology screening to medical aesthetics—are growing; over 70 insurers now recognise Hygeia hospitals for direct settlements. • The group is piloting artificial-intelligence applications in brain-computer interfaces, image diagnostics, supply-chain optimisation and customer service. • Shareholder-return commitment totals RMB1.50 billion over 2026-2028 via share repurchases and/or dividends. This follows RMB200 million of buybacks completed in 2024 and an ongoing RMB300 million programme initiated in 2025. Founder and Chairman Zhu Yiwen lifted his stake to 46.85% after acquiring 3.55 million shares in May 2026.
Positioning and outlook Management re-emphasised Hygeia’s strategy of deepening its oncology focus, expanding specialty disciplines and leveraging free cash flow for disciplined bolt-on acquisitions and ongoing buybacks. Newly built hospitals in the Yangtze River Delta are ramping up, supporting capacity utilisation and reinforcing the company’s standing as China’s largest oncology healthcare group.